Such diversity of actions of GLP‐1 has led to the development of GLP‐1 based therapies for improving glycaemia in type 2 diabetes, for weight loss, and more recently for improving cardiovascular outcomes in patients with diabetes and established cardiovascular disease. The gene discussed is GLP1R; the disease is diabetes mellitus.